Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 1, 2017 - Issue 2
Journal homepage
238
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Long-term inhibition of radiographic joint damage by tofacitinib monotherapy in rheumatoid arthritis patients with rapid radiographic progression about eight cases

Yujiro KonKatayama Orthopedic Rheumatology Clinic, Asahikawa, Japan; ;Sapporo Rheumatology and Immunology Clinic, Sapporo, Japan; ORCID Iconhttp://orcid.org/0000-0002-1779-7365
ORCID Icon,
Kou KatayamaKatayama Orthopedic Rheumatology Clinic, Asahikawa, Japan; Correspondence[email protected]
,
Takanobu OkuboKatayama Orthopedic Rheumatology Clinic, Asahikawa, Japan;
,
Toshikazu SatoKatayama Orthopedic Rheumatology Clinic, Asahikawa, Japan;
,
Richio FukaiSeien Pharmacy, Asahikawa, Japan;
,
Satomi AbeDepartment of Orthopedic Surgery, Asahikawa Medical University, Asahikawa, Japan;
,
Hiroshi ItoDepartment of Orthopedic Surgery, Asahikawa Medical University, Asahikawa, Japan;
,
Shota IchikawaFaculty of Health Science, Hokkaido University, Sapporo, Japan
&
Tamotsu KamishimaFaculty of Health Science, Hokkaido University, Sapporo, Japan
 show all
Pages 35-42 | Received 16 Dec 2016, Accepted 06 Feb 2017, Published online: 17 Mar 2017

References

  • Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–287.
  • Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507.
  • Kremer JM, Li ZG, Hall S, et al. Tofacitinib in combination with non biologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159;253--261.
  • Lee EB, Fleiscmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377–2386.
  • Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–519.
  • van der Heijde D, Tanaka Y, Fleiscmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate. Twelve months data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013; 65:559–570.
  • Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451–460.
  • Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP690, 550) combined with methotrexate in patient with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150–1158.
  • Tanaka Y, Takeuchi T, Nakamura H, et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015;25:514–521.
  • Yamanaka H, Tanaka Y. Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.
  • Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–1167.
  • Strand V, Kremer J, Wallenstein G, et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther. 2015;17:307.
  • Strand V, Burmester GR, Zerbini CAF, et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase 3 trial. Arthritis Care Res. 2015;67:475–483.
  • Vastesaeger N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology (Oxford). 2009;48:1114–1121.
  • Nakashima Y, Tamai M, Kita J, et al. Magnetic resonance imaging bone edema at enrollment predicts rapid radiographic progression in patients with early RA: results from the Nagasaki University Early Arthritis Cohort. J Rheumatol. 2016;43:1278–1284.
  • Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Artritis Rheum. 2014;66:2675–2684.
  • Lee YH, Bae S-C, Song GG. Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatology Int. 2015;35:1965–1974.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.